IL6 and Parkinson disease: Combined with reports of a protective effect of IL-6 in models of traumatic brain injury [29, 30], Parkinson’s disease [31, 32], and in modulating Aβ deposition in Alzheimer’s disease models [33] it is thus possible that the clinical reports of IL-6 elevation in HD at early disease timepoints may reflect a protective rather than pathogenic alteration, and that elevation of IL-6 levels, in certain ranges and timepoints, may have therapeutic benefit in HD.